Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Sera Prognostics (Nasdaq: SERA) reported first quarter 2026 results and key commercial and clinical milestones on May 6, 2026. Highlights include publication of the randomized PRIME trial showing reduced early preterm births (−56% <32 weeks; −32% <35 weeks), NICU admissions (−20%), and neonatal morbidity (−20%). The company launched a third partnership to reach >350 providers, is in active talks with 13 payers across 15 states, and is preparing a CE marking dossier for mid‑year submission. Q1 revenue was $14,000, net loss was $8.4 million, and cash and securities totaled $86.8 million, with a cash runway extended through 2029.
Sera Prognostics (Nasdaq: SERA) will report first quarter fiscal 2026 results on Wednesday, May 6, 2026, after market close and will host a conference call and live webcast at 5:00 p.m. ET. A press release with results and highlights will be distributed before the call.
Live audio and archived replay will be available on the company's Investors page at www.sera.com and the webcast will be archived for one year.
Sera Prognostics (Nasdaq: SERA) reported fourth-quarter and full-year 2025 results and operational progress on March 18, 2026. Key points: landmark PRIME randomized trial showed large reductions in earliest preterm births and neonatal complications, Sera completed a $57.5M follow-on financing in Feb 2025, and year-end cash totaled ~$95.8M, which the company expects to fund operations into 2028.
Full-year revenue was $81,000; 2025 R&D expense declined to $13.2M as the company shifts from pivotal studies toward commercialization.
Sera Prognostics (Nasdaq: SERA) will report fourth quarter and fiscal year 2025 financial results on Wednesday, March 18, 2026, after market close.
The company will host a conference call and live webcast at 5:00 p.m. ET to discuss operational highlights, financial results and key topics. A press release with results will be distributed before the call. Live audio and an archived webcast will be available on the Investors page at www.sera.com for one year.
Sera Prognostics (Nasdaq: SERA) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 1:10 p.m. ET. Management will host a fireside chat and hold one-on-one investor meetings during the March 2-4, 2026 conference in Boston.
A live webcast and replay will be available via the company’s Investors page at www.sera.com.
Sera Prognostics (NASDAQ: SERA) reported PRIME, a randomized trial of 5,018 women published Jan 7, 2026 in PREGNANCY, showing the PreTRM blood test plus targeted interventions reduced earliest preterm births and newborn complications.
Key results: 56% fewer births before 32 weeks, 32% fewer before 35 weeks, 20% fewer NICU admissions, and a 20% reduction in odds of neonatal morbidity. The study found one NICU day saved per 4.2 patients screened and a number-needed-to-screen of 39 to prevent one NICU admission.
Sera Prognostics (NASDAQ: SERA) announced that the PRIME study — Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs — was accepted for publication in a peer-reviewed medical journal on Nov. 24, 2025. The study is described as one of the largest preterm birth studies and its abstract was previously selected as a late-breaking abstract for podium presentation at the Society for Maternal-Fetal Medicine annual meeting earlier in 2025. Management said they will share the PRIME manuscript data upon publication and present findings at upcoming medical meetings and events with research analysts.
Sera Prognostics (Nasdaq: SERA) reported third quarter 2025 results for the period ended Sept 30, 2025, highlighting early commercial progress and PRIME study momentum.
Key points: Q3 revenue $16,000 vs $29,000 year-ago; deferred revenue +$100,000 from a Nevada Medicaid pilot prepayment; total operating expenses $9.0M; net loss $7.8M; and cash and securities ~$102.4M, which the company expects to fund operations through 2028. Company said PRIME data and health-economics results will publish this year and cited a 20% reduction in NICU admissions tied to PreTRM in presentations. Management noted payer discussions across 13 states and the launch of an actively enrolling Medicaid pilot in Nevada.
Sera Prognostics (Nasdaq:SERA) announced it will report third quarter fiscal 2025 financial results on Thursday, November 13, 2025 after market close.
The company will host a conference call and live webcast to discuss operational highlights and financial results at 5:00 p.m. Eastern Time. A press release with results and highlights will be distributed before the call. US callers: (800) 836-8184; international callers: (646) 357-8785. Webcast registration: https://app.webinar.net/1qop01GkwO2. Live audio and a webcast archive will be available on the Investors page at www.sera.com and the webcast will be archived for one year.
Sera Prognostics (NASDAQ:SERA) has appointed Dr. Tiffany Inglis as Chief Medical Officer. Dr. Inglis, who previously held clinical leadership positions at Elevance Health and Carelon Health, brings extensive experience in women's and children's health programs.
As a former practicing OBGYN with over a decade of experience, Dr. Inglis will lead Sera's clinical operations to advance the company's position in women's health diagnostics, particularly focusing on the PreTRM® Test. Her appointment comes at a crucial time as the company prepares for the publication of the PRIME study and launches pilots with state Medicaid programs.
Dr. Inglis received her medical degree from the Medical College of Ohio in 2002 and completed her Obstetrics and Gynecology residency at Riverside Methodist Hospital in 2006. Her expertise includes implementing cost-effective solutions for improving maternal and neonatal outcomes.